[Chemotherapy with bevacizumab (BV)+modified FOLFOX6 for unresectable colorectal cancer].

We examined efficacy and safety of bevacizumab (BV)+modified FOLFOX6 (mFOLFOX6) regimen for unresectable colorectal cancer. We had 16 patients: liver metastases 8, lung metastases 4, local recurrences 2, and lymph node metastases 2, as for evaluable lesions. The response rate was 46.6%, and disease control rate was 86.6%. Hepatic metastatectomy was done in two cases after PR response. There was 1 infusion related reaction case, 1 tumor bleeding and 1 anal fistula as the adverse events. In conclusion, the BV+mFOLFOX6 is one of the effective and feasible regimens for unresectable colorectal cancer.